Fungal skin infections, or dermatomycoses, are associated with a broad range of pathogens. Involvement of gram-positive bacteria is often suspected in dermatomycoses. Inflammation plays an important role in dermatomycoses, displaying a close association between frequent inflammation and reduced skin-related quality of life.
Isoconazole nitrate ( ISN ) is a broad-spectrum antimicrobial agent with a highly effective antimycotic and gram-positive antibacterial activity, a rapid rate of absorption and low systemic exposure potential.
Isoconazole nitrate is effective against pathogens involved in dermatomycoses, with minimum inhibitory concentrations well below the concentration of Isoconazole nitrate in skin and hair follicles.
The combination of the corticosteroid Diflucortolone valerate with Isoconazole nitrate ( Travocort ) increases the local bioavailability of Isoconazole nitrate.
Compared with Isoconazole nitrate monotherapy, Travocort has a faster onset of antimycotic action, faster relief of itch and other inflammatory symptoms, improved overall therapeutic benefits and earlier mycological cure rate.
Travocort is effective in the treatment of inflammatory mycotic infections, and also in the eradication of accompanied gram-positive bacterial infections.
The rapid improvement observed with Travocort treatment, combined with favourable safety and tolerability, results in higher patient satisfaction, and therefore, can be an effective tool to increase treatment adherence in patients with dermatomycoses accompanied by inflammatory signs and symptoms. ( Xagena )
Veraldi S, Mycoses 2013;56 Suppl 1:3-15